Mouse Anti-Human Monoclonal Antibody Against Glypican-3
AssigneesUniversity of Washington, Fred Hutchinson Cancer Center
InventorsJames O. Park, Elizabeth Wayner
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure provide an antibody comprising a light chain variable domain and a heavy chain variable domain. The light chain variable domain comprises a CDRL1 with an amino acid sequence as set forth in SEQ ID NO:8; a CDRL2 with an amino acid sequence as set forth in SEQ ID NO:10; and a CDRL3 with an amino acid sequence as set forth in SEQ ID NO:12. The heavy cham variable domain comprises a CDRH1 with an amino acid sequence as set forth in SEQ ID NO:4; a CDRH2 with an amino acid sequence as set forth in SEQ ID NO:16; and a CDRH3 with an amino acid sequence as set forth in SEQ ID NO:18; wherein the antibody specifically binds glypican-3 (GPC3).
Claims21
An antibody, comprising:
- a light chain variable domain comprising:
- a CDRL1 with an amino acid sequence as set forth in SEQ ID NO:8;
- a CDRL2 with an amino acid sequence as set forth in SEQ ID NO:10;
- and
- a CDRL3 with an amino acid sequence as set forth in SEQ ID NO:12;
- and
- a heavy chain variable domain comprising:
- a CDRH1 with an amino acid sequence as set forth in SEQ ID NO:4;
- a CDRH2 with an amino acid sequence as set forth in SEQ ID NO:16;
- and
- a CDRH3 with an amino acid sequence as set forth in SEQ ID NO:18;
- wherein the antibody specifically binds glypican-3 (GPC3).
(canceled)
Dependencies are inferred from the claim text.